Gene Expression Profiling as a Novel Diagnostic Tool for Neurodegenerative Disorders

Area of Science:

• Neuroscience
• Genetics
• Biomarker Discovery

Background:

• Effective diagnostic biomarkers for neurodegenerative disorders (NDDs) are currently lacking.
• Accurate and early diagnosis is crucial for managing NDDs like Alzheimer's disease (AD), Parkinson's disease (PD), and vascular dementia (VaD).

Purpose of the Study:

• To establish gene expression profiles for the diagnosis of AD, PD, and VaD/mixed dementia.
• To evaluate the diagnostic accuracy of specific mRNA biomarkers for these NDDs.
• To explore gene expression analysis as a potential liquid biopsy alternative.

Main Methods:

• Gene expression profiling was performed on patients with AD, PD, and VaD/mixed dementia.
• Analysis focused on mRNA expression levels of APOE, PSEN1, ABCA7, PICALM, and SNCA.
• Diagnostic accuracy of individual gene expressions and the impact of APOE genotype were assessed.

Main Results:

• Decreased APOE, PSEN1, and ABCA7 mRNA in AD patients.
• Increased PICALM and decreased ABCA7 mRNA in VaD/mixed dementia patients.
• Increased SNCA mRNA in PD patients.
• APOE, ABCA7, and SNCA mRNA showed significant diagnostic accuracy for specific NDDs.
• OPRK1, NTRK2, and LRRK2 mRNA levels did not differ between healthy subjects and NDD patients.

Conclusions:

• Gene expression analysis holds diagnostic value for neurodegenerative disorders.
• Specific mRNA biomarkers like APOE, PSEN1, ABCA7, and SNCA can aid in differentiating NDDs.
• This approach offers a potential non-invasive, liquid biopsy alternative for NDD diagnosis.